Phibro Animal Health Corp.
- PAHC ยท Nasdaq
- Pharmaceutical Preparations
- Teaneck, NJ
- 2,605 employees
- CIK 0001069899
Updated from SEC filings through
Top things to know
Executives
-
Daniel M. Bendheim President and Chief Executive Officer 10-K, 2026-08-26 -
Glenn David Chief Financial Officer 4/A, 2026-09-17 - Glenn C. David Chief Financial Officer 10-K, 2026-08-26
- Larry Lee Miller Chief Operating Officer 4/A, 2026-09-17
-
Jonathan Bendheim Executive Vice President, Global Technologies and Talent 10-K, 2026-08-26 -
Jack C. Bendheim Executive Chairman 10-K, 2026-08-26
Phibro Animal Health Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Teaneck, NJ. It trades as PAHC on Nasdaq. Revenue was $1.5B in the fiscal year ending June 30, 2026, +17.1% from the year before. It reported about 2,605 employees. Daniel M. Bendheim is President and Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.5B 10-K, 2026-08-26 | $1.3B 10-K, 2026-08-26 | $1.0B 10-K, 2026-08-26 | $978M 10-K, 2025-08-27 | $942M 10-K, 2024-08-28 |
| Operating income | $194M 10-K, 2026-08-26 | $110M 10-K, 2026-08-26 | $53.3M 10-K, 2026-08-26 | $71.8M 10-K, 2025-08-27 | $79.0M 10-K, 2024-08-28 |
| SG&A | $318M 10-K, 2026-08-26 | $289M 10-K, 2026-08-26 | $260M 10-K, 2026-08-26 | $226M 10-K, 2025-08-27 | $206M 10-K, 2024-08-28 |
| Net income | $99.7M 10-K, 2026-08-26 | $48.3M 10-K, 2026-08-26 | $2.4M 10-K, 2026-08-26 | $32.6M 10-K, 2025-08-27 | $49.2M 10-K, 2024-08-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Daniel M. Bendheim | President and Chief Executive Officer | 10-K, 2026-08-26 |
| Glenn David Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance at Zoetis Inc. | Chief Financial Officer | 4/A, 2026-09-17 |
| Glenn C. David | Chief Financial Officer | 10-K, 2026-08-26 |
 Judith A. Weinstein | Named in proxy bio: Senior Vice President, General Counsel and Corporate Secretary | DEF 14A, 2026-09-18 |
| Larry L. Miller Chief Operating Officer at Phibro Animal Health Corporation | Named in proxy bio: Chief Operating Officer | DEF 14A, 2026-09-18 |
 Lisa A. Escudero HR Executive Business Partner - builds high performance and engaged organizations | Named in proxy bio: Senior Vice President, Human Resources | DEF 14A, 2026-09-18 |
| Larry Lee Miller | Chief Operating Officer | 4/A, 2026-09-17 |
| Jonathan Bendheim | Executive Vice President, Global Technologies and Talent | 10-K, 2026-08-26 |
| Anthony Andolino | Named in proxy bio: Vice President Finance and Treasurer | DEF 14A, 2025-09-19 |
| Jack C. Bendheim | Executive Chairman | 10-K, 2026-08-26 |
 Patrick Rodriguez | VP Finance and Treasurer | 4, 2026-08-10 |
| Jack Bendheim | Executive Chairman | 4, 2026-08-10 |
| Alejandro Bernal | Director | 10-K, 2026-08-26 |
| Carol A. Wrenn | Director | 10-K, 2026-08-26 |
| E. Thomas Corcoran | Director | 10-K, 2026-08-26 |
| Mary Lou Malanoski | Director | 10-K, 2026-08-26 |
What Phibro Animal Health Corp does
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs.
Shares and governance
| Public float | $764M (as of December 31, 2025) | 10-K, August 26, 2026 |
|---|---|---|
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting November 3, 2026 (filed September 18, 2026) | DEF 14A, September 18, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| May 29, 2026 | E. Thomas Corcoran Director | Buy | 10,000 | $318K | Form 4, June 2, 2026 |
| May 7, 2026 | Jack Bendheim President and CEO | Sale | 18,608 | $1.0M | Form 4, May 7, 2026 |
| April 30, 2026 | Jack Bendheim President and CEO | Sale | 21,120 | $1.1M | Form 4, April 30, 2026 |
| April 23, 2026 | Jack Bendheim President and CEO | Sale | 21,120 | $1.2M | Form 4, April 23, 2026 |
| April 16, 2026 | Jack Bendheim President and CEO | Sale | 21,120 | $1.2M | Form 4, April 16, 2026 |
| March 31, 2026 | Jack Bendheim President and CEO | Sale | 14,080 | $757K | Form 4, March 31, 2026 |
| March 26, 2026 | Jack Bendheim President and CEO | Sale | 21,120 | $1.2M | Form 4, March 26, 2026 |
| March 19, 2026 | Jack Bendheim President and CEO | Sale | 22,880 | $1.2M | Form 4, March 19, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-11-03
- Item 8.01 Other events
- 8-K filed 2026-08-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-28
- Item 8.01 Other events
- 8-K filed 2026-06-26
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-05
- Item 8.01 Other events
- 8-K filed 2026-04-30
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-04-27
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-14
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Phibro Animal Health Corp
- What does Phibro Animal Health Corp do?
- In its own words, from Item 1 of its 10-K: "Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs."
- What is Phibro Animal Health Corp's revenue?
- $1.5B for the fiscal year ending June 30, 2026, from its 10-K filed August 26, 2026.
- Is Phibro Animal Health Corp profitable?
- Phibro Animal Health Corp reported net income of $99.7M for the fiscal year ending June 30, 2026.
- How many employees does Phibro Animal Health Corp have?
- About 2,605 as of June 30, 2026, as stated in its annual report.
- Who is the CEO of Phibro Animal Health Corp?
- Daniel M. Bendheim, President and Chief Executive Officer, as named in a 10-K filed August 26, 2026.
- Who is the CFO of Phibro Animal Health Corp?
- Glenn David, Chief Financial Officer, as named in a 4/A filed September 17, 2026.
- Where is Phibro Animal Health Corp headquartered?
- Teaneck, NJ.
- What is Phibro Animal Health Corp's stock ticker?
- PAHC on Nasdaq.
- What industry is Phibro Animal Health Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Phibro Animal Health Corp's website?
- pahc.com.
- When does Phibro Animal Health Corp report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Phibro Animal Health Corp a public company?
- Yes. Phibro Animal Health Corp files with the SEC under CIK 0001069899 and trades as PAHC.
- Who audits Phibro Animal Health Corp?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- What is Phibro Animal Health Corp's public float?
- $764M as of December 31, 2025, as reported on the cover of its 10-K filed August 26, 2026.
- How many business segments does Phibro Animal Health Corp report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Phibro Animal Health Corp's annual shareholder meeting?
- November 3, 2026, per its proxy statement (DEF 14A) filed September 18, 2026.
- Have Phibro Animal Health Corp insiders traded stock recently?
- Since November 13, 2025, officers and directors reported 28 open-market sales worth about $25.0M and 1 purchase worth about $318K on Forms 4 and 5. The most recent: E. Thomas Corcoran (Director) bought 10,000 shares on May 29, 2026.